IL125442A - A method for selecting optimal HIV inhibitors for use in the chemotherapy of HIV-positive patients - Google Patents
A method for selecting optimal HIV inhibitors for use in the chemotherapy of HIV-positive patientsInfo
- Publication number
- IL125442A IL125442A IL12544297A IL12544297A IL125442A IL 125442 A IL125442 A IL 125442A IL 12544297 A IL12544297 A IL 12544297A IL 12544297 A IL12544297 A IL 12544297A IL 125442 A IL125442 A IL 125442A
- Authority
- IL
- Israel
- Prior art keywords
- hiv
- inhibitors
- chimeric
- inhibitor
- patient
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 89
- 238000000034 method Methods 0.000 title claims abstract description 81
- 241000700605 Viruses Species 0.000 claims abstract description 41
- 230000035945 sensitivity Effects 0.000 claims abstract description 40
- 108700004029 pol Genes Proteins 0.000 claims abstract description 31
- 101150088264 pol gene Proteins 0.000 claims abstract description 31
- 238000002512 chemotherapy Methods 0.000 claims abstract description 28
- 102000004190 Enzymes Human genes 0.000 claims abstract description 18
- 108090000790 Enzymes Proteins 0.000 claims abstract description 18
- 239000012620 biological material Substances 0.000 claims abstract description 14
- 230000002441 reversible effect Effects 0.000 claims abstract description 13
- 108020000999 Viral RNA Proteins 0.000 claims abstract description 9
- 208000015181 infectious disease Diseases 0.000 claims abstract description 8
- 238000011282 treatment Methods 0.000 claims abstract description 7
- 238000012258 culturing Methods 0.000 claims abstract description 5
- 238000000338 in vitro Methods 0.000 claims abstract description 3
- 230000000007 visual effect Effects 0.000 claims abstract description 3
- 102100034343 Integrase Human genes 0.000 claims description 62
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 claims description 59
- 229940079593 drug Drugs 0.000 claims description 55
- 239000003814 drug Substances 0.000 claims description 55
- 210000004027 cell Anatomy 0.000 claims description 37
- 108091005804 Peptidases Proteins 0.000 claims description 24
- 239000013612 plasmid Substances 0.000 claims description 19
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 18
- 239000000137 peptide hydrolase inhibitor Substances 0.000 claims description 18
- 238000001890 transfection Methods 0.000 claims description 18
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 claims description 16
- 239000004365 Protease Substances 0.000 claims description 15
- 239000002777 nucleoside Substances 0.000 claims description 13
- 239000000463 material Substances 0.000 claims description 12
- 238000007857 nested PCR Methods 0.000 claims description 12
- 150000003833 nucleoside derivatives Chemical class 0.000 claims description 12
- 230000008901 benefit Effects 0.000 claims description 11
- 230000003612 virological effect Effects 0.000 claims description 11
- 229940124524 integrase inhibitor Drugs 0.000 claims description 10
- 239000002850 integrase inhibitor Substances 0.000 claims description 10
- NQDJXKOVJZTUJA-UHFFFAOYSA-N nevirapine Chemical compound C12=NC=CC=C2C(=O)NC=2C(C)=CC=NC=2N1C1CC1 NQDJXKOVJZTUJA-UHFFFAOYSA-N 0.000 claims description 8
- 108010061833 Integrases Proteins 0.000 claims description 6
- 238000004520 electroporation Methods 0.000 claims description 6
- SWUARLUWKZWEBQ-VQHVLOKHSA-N phenethyl caffeate Chemical compound C1=C(O)C(O)=CC=C1\C=C\C(=O)OCCC1=CC=CC=C1 SWUARLUWKZWEBQ-VQHVLOKHSA-N 0.000 claims description 6
- SWUARLUWKZWEBQ-UHFFFAOYSA-N phenylethyl ester of caffeic acid Natural products C1=C(O)C(O)=CC=C1C=CC(=O)OCCC1=CC=CC=C1 SWUARLUWKZWEBQ-UHFFFAOYSA-N 0.000 claims description 6
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims description 5
- 210000001744 T-lymphocyte Anatomy 0.000 claims description 5
- 229960001936 indinavir Drugs 0.000 claims description 5
- CBVCZFGXHXORBI-PXQQMZJSSA-N indinavir Chemical compound C([C@H](N(CC1)C[C@@H](O)C[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H]2C3=CC=CC=C3C[C@H]2O)C(=O)NC(C)(C)C)N1CC1=CC=CN=C1 CBVCZFGXHXORBI-PXQQMZJSSA-N 0.000 claims description 5
- 238000010839 reverse transcription Methods 0.000 claims description 5
- 229960000311 ritonavir Drugs 0.000 claims description 5
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims description 5
- 229960001852 saquinavir Drugs 0.000 claims description 5
- QWAXKHKRTORLEM-UGJKXSETSA-N saquinavir Chemical compound C([C@@H]([C@H](O)CN1C[C@H]2CCCC[C@H]2C[C@H]1C(=O)NC(C)(C)C)NC(=O)[C@H](CC(N)=O)NC(=O)C=1N=C2C=CC=CC2=CC=1)C1=CC=CC=C1 QWAXKHKRTORLEM-UGJKXSETSA-N 0.000 claims description 5
- 210000001519 tissue Anatomy 0.000 claims description 5
- ZNFFMCYSMBXZQU-NSHDSACASA-N 5-chloro-8-methyl-7-(3-methyl-but-2-enyl)-6,7,8,9-tetrahydro-2h-2,7,9a-triaza-benzo[cd]azulene-1-thione Chemical compound C1N(CC=C(C)C)[C@@H](C)CN2C(=S)NC3=CC=C(Cl)C1=C32 ZNFFMCYSMBXZQU-NSHDSACASA-N 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 229950006243 loviride Drugs 0.000 claims description 4
- CJPLEFFCVDQQFZ-UHFFFAOYSA-N loviride Chemical compound CC(=O)C1=CC=C(C)C=C1NC(C(N)=O)C1=C(Cl)C=CC=C1Cl CJPLEFFCVDQQFZ-UHFFFAOYSA-N 0.000 claims description 4
- 210000001124 body fluid Anatomy 0.000 claims description 3
- 239000010839 body fluid Substances 0.000 claims description 3
- 230000001788 irregular Effects 0.000 claims description 3
- 229960000689 nevirapine Drugs 0.000 claims description 3
- 210000002966 serum Anatomy 0.000 claims description 3
- 229950011282 tivirapine Drugs 0.000 claims description 3
- PKVZBNCYEICAQP-UHFFFAOYSA-N Mecamylamine hydrochloride Chemical compound Cl.C1CC2C(C)(C)C(NC)(C)C1C2 PKVZBNCYEICAQP-UHFFFAOYSA-N 0.000 claims description 2
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 claims description 2
- 239000008280 blood Substances 0.000 claims description 2
- 210000005013 brain tissue Anatomy 0.000 claims description 2
- 238000000423 cell based assay Methods 0.000 claims description 2
- 230000007423 decrease Effects 0.000 claims description 2
- 239000012530 fluid Substances 0.000 claims description 2
- 210000002751 lymph Anatomy 0.000 claims description 2
- 210000000582 semen Anatomy 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 241000580858 Simian-Human immunodeficiency virus Species 0.000 claims 27
- 125000002091 cationic group Chemical group 0.000 claims 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 94
- HBOMLICNUCNMMY-XLPZGREQSA-N zidovudine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](N=[N+]=[N-])C1 HBOMLICNUCNMMY-XLPZGREQSA-N 0.000 description 17
- 230000035772 mutation Effects 0.000 description 16
- 238000003752 polymerase chain reaction Methods 0.000 description 16
- 229960002555 zidovudine Drugs 0.000 description 15
- 230000000973 chemotherapeutic effect Effects 0.000 description 14
- 230000008859 change Effects 0.000 description 12
- 230000006798 recombination Effects 0.000 description 12
- 238000005215 recombination Methods 0.000 description 12
- 238000002560 therapeutic procedure Methods 0.000 description 12
- 239000013598 vector Substances 0.000 description 12
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 11
- 239000000047 product Substances 0.000 description 10
- 108090000623 proteins and genes Proteins 0.000 description 10
- 235000001014 amino acid Nutrition 0.000 description 9
- 150000001413 amino acids Chemical class 0.000 description 9
- 239000002299 complementary DNA Substances 0.000 description 8
- 108020004414 DNA Proteins 0.000 description 7
- WHBIGIKBNXZKFE-UHFFFAOYSA-N delavirdine Chemical compound CC(C)NC1=CC=CN=C1N1CCN(C(=O)C=2NC3=CC=C(NS(C)(=O)=O)C=C3C=2)CC1 WHBIGIKBNXZKFE-UHFFFAOYSA-N 0.000 description 7
- 238000012217 deletion Methods 0.000 description 7
- 230000037430 deletion Effects 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000002955 isolation Methods 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- 239000002773 nucleotide Substances 0.000 description 7
- 125000003729 nucleotide group Chemical group 0.000 description 7
- 230000001566 pro-viral effect Effects 0.000 description 7
- 101150104269 RT gene Proteins 0.000 description 6
- 238000010276 construction Methods 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 6
- 229940124821 NNRTIs Drugs 0.000 description 5
- 230000003321 amplification Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 238000003199 nucleic acid amplification method Methods 0.000 description 5
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 5
- 239000000523 sample Substances 0.000 description 5
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 4
- XNKLLVCARDGLGL-JGVFFNPUSA-N Stavudine Chemical compound O=C1NC(=O)C(C)=CN1[C@H]1C=C[C@@H](CO)O1 XNKLLVCARDGLGL-JGVFFNPUSA-N 0.000 description 4
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 description 4
- 238000013459 approach Methods 0.000 description 4
- 238000002648 combination therapy Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 239000000890 drug combination Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- BXZVVICBKDXVGW-NKWVEPMBSA-N Didanosine Chemical compound O1[C@H](CO)CC[C@@H]1N1C(NC=NC2=O)=C2N=C1 BXZVVICBKDXVGW-NKWVEPMBSA-N 0.000 description 3
- 101710203526 Integrase Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000000798 anti-retroviral effect Effects 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 230000000120 cytopathologic effect Effects 0.000 description 3
- -1 ddl Chemical compound 0.000 description 3
- 229960002656 didanosine Drugs 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000012634 fragment Substances 0.000 description 3
- 238000003205 genotyping method Methods 0.000 description 3
- 230000006801 homologous recombination Effects 0.000 description 3
- 238000002744 homologous recombination Methods 0.000 description 3
- 238000011835 investigation Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- VMGAPWLDMVPYIA-HIDZBRGKSA-N n'-amino-n-iminomethanimidamide Chemical compound N\N=C\N=N VMGAPWLDMVPYIA-HIDZBRGKSA-N 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- BOLDJAUMGUJJKM-LSDHHAIUSA-N renifolin D Natural products CC(=C)[C@@H]1Cc2c(O)c(O)ccc2[C@H]1CC(=O)c3ccc(O)cc3O BOLDJAUMGUJJKM-LSDHHAIUSA-N 0.000 description 3
- 238000003757 reverse transcription PCR Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 2
- 102100029457 Adenine phosphoribosyltransferase Human genes 0.000 description 2
- 108010024223 Adenine phosphoribosyltransferase Proteins 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- 108091034117 Oligonucleotide Proteins 0.000 description 2
- 206010034133 Pathogen resistance Diseases 0.000 description 2
- 238000005349 anion exchange Methods 0.000 description 2
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 239000004599 antimicrobial Substances 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 108010058966 bacteriophage T7 induced DNA polymerase Proteins 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 238000005259 measurement Methods 0.000 description 2
- 230000001404 mediated effect Effects 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 238000002703 mutagenesis Methods 0.000 description 2
- 231100000350 mutagenesis Toxicity 0.000 description 2
- 229940127073 nucleoside analogue Drugs 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 229940063627 rescriptor Drugs 0.000 description 2
- 229940064914 retrovir Drugs 0.000 description 2
- 238000013207 serial dilution Methods 0.000 description 2
- 238000009097 single-agent therapy Methods 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000004448 titration Methods 0.000 description 2
- 229940098802 viramune Drugs 0.000 description 2
- ZDSRFXVZVHSYMA-CMOCDZPBSA-N (2s)-2-[[(2s)-2-[[(2s)-2-[[(2s)-2-amino-3-(4-hydroxyphenyl)propanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-carboxybutanoyl]amino]pentanedioic acid Chemical compound C([C@H](N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCC(O)=O)C(O)=O)C1=CC=C(O)C=C1 ZDSRFXVZVHSYMA-CMOCDZPBSA-N 0.000 description 1
- BFSVOASYOCHEOV-UHFFFAOYSA-N 2-diethylaminoethanol Chemical compound CCN(CC)CCO BFSVOASYOCHEOV-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 240000006108 Allium ampeloprasum Species 0.000 description 1
- 235000005254 Allium ampeloprasum Nutrition 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 108010010369 HIV Protease Proteins 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 238000000134 MTT assay Methods 0.000 description 1
- 231100000002 MTT assay Toxicity 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 102220500387 Neutral and basic amino acid transport protein rBAT_M41Y_mutation Human genes 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 101710115215 Protease inhibitors Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 108010006785 Taq Polymerase Proteins 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 244000126002 Ziziphus vulgaris Species 0.000 description 1
- 235000008529 Ziziphus vulgaris Nutrition 0.000 description 1
- 229960004748 abacavir Drugs 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 125000003275 alpha amino acid group Chemical group 0.000 description 1
- 230000003698 anagen phase Effects 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000010261 cell growth Effects 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 238000012364 cultivation method Methods 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000009109 curative therapy Methods 0.000 description 1
- 238000011461 current therapy Methods 0.000 description 1
- 229960005319 delavirdine Drugs 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002532 enzyme inhibitor Substances 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229960001627 lamivudine Drugs 0.000 description 1
- JTEGQNOMFQHVDC-NKWVEPMBSA-N lamivudine Chemical compound O=C1N=C(N)C=CN1[C@H]1O[C@@H](CO)SC1 JTEGQNOMFQHVDC-NKWVEPMBSA-N 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 238000000424 optical density measurement Methods 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 238000012247 phenotypical assay Methods 0.000 description 1
- 230000008092 positive effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- WTTIBCHOELPGFK-LBPRGKRZSA-N r82150 Chemical compound C1N(CC=C(C)C)[C@@H](C)CN2C(=S)NC3=CC=CC1=C32 WTTIBCHOELPGFK-LBPRGKRZSA-N 0.000 description 1
- 101150079601 recA gene Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108091008146 restriction endonucleases Proteins 0.000 description 1
- 102200131341 rs267607614 Human genes 0.000 description 1
- 102220011161 rs727504317 Human genes 0.000 description 1
- 102200069353 rs8103142 Human genes 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000005063 solubilization Methods 0.000 description 1
- 230000007928 solubilization Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229960001203 stavudine Drugs 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 230000002110 toxicologic effect Effects 0.000 description 1
- 231100000027 toxicology Toxicity 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 108010068794 tyrosyl-tyrosyl-glutamyl-glutamic acid Proteins 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 229960000523 zalcitabine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2740/00—Reverse transcribing RNA viruses
- C12N2740/00011—Details
- C12N2740/10011—Retroviridae
- C12N2740/16011—Human Immunodeficiency Virus, HIV
- C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
- Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP96200175 | 1996-01-26 | ||
| PCT/IB1997/000071 WO1997027480A1 (en) | 1996-01-26 | 1997-01-24 | Method of managing the chemotherapy of patients who are hiv positive based on the phenotypic drug sensitivity of human hiv strains |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL125442A0 IL125442A0 (en) | 1999-03-12 |
| IL125442A true IL125442A (en) | 2002-03-10 |
Family
ID=8223611
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL12544297A IL125442A (en) | 1996-01-26 | 1997-01-24 | A method for selecting optimal HIV inhibitors for use in the chemotherapy of HIV-positive patients |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US6221578B1 (pl) |
| EP (1) | EP0877937B1 (pl) |
| KR (1) | KR100495690B1 (pl) |
| CN (2) | CN1991365A (pl) |
| AT (1) | ATE217971T1 (pl) |
| AU (1) | AU717755B2 (pl) |
| BG (1) | BG102710A (pl) |
| BR (1) | BR9707204A (pl) |
| CZ (1) | CZ292899B6 (pl) |
| DE (1) | DE69712731T2 (pl) |
| ES (1) | ES2177922T3 (pl) |
| HU (1) | HU226203B1 (pl) |
| IL (1) | IL125442A (pl) |
| IS (1) | IS4799A (pl) |
| NO (1) | NO321329B1 (pl) |
| NZ (1) | NZ325912A (pl) |
| PL (1) | PL186473B1 (pl) |
| SK (1) | SK283878B6 (pl) |
| TR (1) | TR199801443T2 (pl) |
| WO (1) | WO1997027480A1 (pl) |
| ZA (1) | ZA97669B (pl) |
Families Citing this family (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5843946A (en) | 1992-08-25 | 1998-12-01 | G.D. Searle & Co. | α-and β-amino acid hydroxyethylamino sulfonamides useful as retroviral protease inhibitors |
| US20030220276A1 (en) * | 1995-05-16 | 2003-11-27 | Opendra Narayan | HIV vaccine and method of use |
| US6242187B1 (en) | 1996-01-29 | 2001-06-05 | Virologic, Inc. | Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening |
| US20070010471A1 (en) * | 1997-05-02 | 2007-01-11 | Opendra Narayan | HIV DNA vaccine |
| EP1012334A4 (en) * | 1997-07-30 | 2004-12-29 | Virologic Inc | COMPOSITIONS AND METHODS FOR DETERMINING SENSITIVITY AND RESISTANCE TO ANTIVIRAL DRUGS, AND SCREENING FOR ANTIVIRAL DRUGS |
| CA2329140A1 (en) * | 1998-05-26 | 1999-12-02 | Virologic, Inc. | Means and methods for monitoring non-nucleoside reverse transcriptase inhibitor antiretroviral therapy |
| EP1185712B8 (en) * | 1999-05-28 | 2005-10-19 | Virco Bvba | New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance |
| US6800437B1 (en) | 1999-08-06 | 2004-10-05 | Tibotec Bvba | Method of monitoring a biological system by labeling with an apo metal binding protein |
| EP1109019A1 (en) * | 1999-12-15 | 2001-06-20 | BioStrands S.r.l. | Method to evaluate the sensitivity of HIV variants to drugs able to inhibit the HIV protease |
| WO2001057245A2 (en) * | 2000-02-04 | 2001-08-09 | K.U.Leuven Research & Development | Hiv-1 resistance assay |
| GB0009374D0 (en) * | 2000-04-14 | 2000-05-31 | Glaxo Group Ltd | Phenotyping assay and reagents therefor |
| AU2001260224A1 (en) * | 2000-04-18 | 2001-10-30 | Virco Bvba | Methods for measuring drug resistance |
| AU2001256318B8 (en) * | 2000-04-20 | 2007-03-22 | Virco Bvba | Method for mutation detection in HIV using pol sequencing |
| US6800463B1 (en) * | 2000-04-20 | 2004-10-05 | Virco Bvba | Method for mutation detection in HIV-1 using pol sequencing |
| US6582901B2 (en) * | 2000-04-26 | 2003-06-24 | Bruce K. Patterson | Cell specific anti-viral drug susceptibility test using tagged permissive target cells |
| US7058616B1 (en) | 2000-06-08 | 2006-06-06 | Virco Bvba | Method and system for predicting resistance of a disease to a therapeutic agent using a neural network |
| BR0111575A (pt) * | 2000-06-12 | 2003-06-24 | Virologic Inc | Meios e métodos para monitorar a terapia anti-retroviral e orientar as decisões terapêuticas no tratamento de hiv/aids |
| US6582920B2 (en) * | 2000-09-01 | 2003-06-24 | Gen-Probe Incorporated | Amplification of HIV-1 RT sequences for detection of sequences associated with drug-resistance mutations |
| MXPA03003476A (es) * | 2000-10-20 | 2004-09-10 | Virco Bvba | Nuevos perfiles mutacionales en transcriptasa inversa de vih-1 correlacionan con resistencia fenotipica a farmaco. |
| EP1340075B1 (en) * | 2000-10-20 | 2009-01-28 | Virco Bvba | Establishment of biological cut-off values for predicting resistance to therapy |
| US7306901B2 (en) | 2001-08-08 | 2007-12-11 | Tibotec Pharmaceuticals, Ltd. | Methods and means for assessing HIV envelope inhibitor therapy |
| US6958211B2 (en) * | 2001-08-08 | 2005-10-25 | Tibotech Bvba | Methods of assessing HIV integrase inhibitor therapy |
| DE60225587T2 (de) | 2001-11-08 | 2009-04-02 | Aaron Diamond Aids Research Center | Protease assay zur kontrolle medikamentöser therapie |
| EP1520247B1 (en) | 2002-07-01 | 2009-05-27 | Tibotec Pharmaceuticals Ltd. | Mutational profiles in hiv-1 protease correlated with phenotypic drug resistance |
| WO2004003223A2 (en) * | 2002-07-01 | 2004-01-08 | Tibotec Pharmaceuticals Ltd. | New mutational profiles in hiv-1 reverse transcriptase correlated with phenotypic drug resistance |
| US8099262B2 (en) * | 2004-03-02 | 2012-01-17 | Virco Bvba | Estimation of clinical cut-offs |
| CA2631881C (en) | 2005-12-07 | 2015-03-24 | Tibotec Pharmaceuticals Ltd. | Methods, plasmid vectors and primers for assessing hiv viral fitness |
| AU2007239535B2 (en) * | 2006-04-14 | 2012-12-20 | Tibotec Pharmaceuticals Ltd. | Methods and means for assessing HIV gag/protease inhibitor therapy |
| EP2162745A1 (en) | 2007-05-25 | 2010-03-17 | Tibotec Pharmaceuticals | New mutational profile in hiv-1 gag cleavage site correlated with phenotypic drug resistance |
| EP2342363B1 (en) | 2008-10-06 | 2015-06-10 | Janssen Diagnostics BVBA | Method for determining drug resistance mutations in any of the non-structural protein regions ns3 to ns5b of hepatitis c virus (hcv) for genotypes 1 to 6 |
| US20120064514A1 (en) * | 2009-05-12 | 2012-03-15 | Virco Bvba | Hiv-1-c resistance monitoring |
| CN107085093B (zh) * | 2017-03-24 | 2019-06-21 | 西藏诺迪康药业股份有限公司 | 重组人白细胞介素1受体拮抗剂滴眼液生物学活性的检测方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3875396A (en) * | 1973-11-12 | 1975-04-01 | Illuminite Corp | Illuminated clipboard |
| US4675147A (en) * | 1983-04-06 | 1987-06-23 | Westinghouse Electic Corp. | Generating an integrated graphic display of the safety status of a complex process plant |
| US5716826A (en) * | 1988-03-21 | 1998-02-10 | Chiron Viagene, Inc. | Recombinant retroviruses |
| US5665577A (en) | 1989-02-06 | 1997-09-09 | Dana-Farber Cancer Institute | Vectors containing HIV packaging sequences, packaging defective HIV vectors, and uses thereof |
| ES2166748T3 (es) | 1989-05-25 | 2002-05-01 | Novartis Ag | Represor multivalente de la funcion genica. |
| US5401629A (en) | 1990-08-07 | 1995-03-28 | The Salk Institute Biotechnology/Industrial Associates, Inc. | Assay methods and compositions useful for measuring the transduction of an intracellular signal |
| JPH05148202A (ja) * | 1991-04-10 | 1993-06-15 | Tsumura & Co | 新規な化合物およびその医薬としての用途 |
| WO1993023574A1 (en) | 1992-05-14 | 1993-11-25 | Kozal Michael J | Polymerase chain reaction assays for monitoring antiviral therapy |
| US5733720A (en) | 1992-06-18 | 1998-03-31 | Washington University | Genetically engineered cell lines for detecting infectious herpesvirus and methods therefor |
| WO1994001584A1 (en) | 1992-07-06 | 1994-01-20 | President And Fellows Of Harvard College | Methods and diagnostic kits for determining toxicity utilizing bacterial stress promoters fused to reporter genes |
| US5344846A (en) | 1992-12-30 | 1994-09-06 | The United States Of America As Represented By The Department Of Health And Human Services | Compositions and methods for inhibiting deoxyhypusine synthase and the growth of cells |
| US5591579A (en) | 1993-12-21 | 1997-01-07 | Washington University | Indicator cell line for detecting RNA viruses and method therefor |
| US6063562A (en) | 1994-09-16 | 2000-05-16 | Sepracor, Inc. | In vitro method for predicting the evolutionary response of HIV protease to a drug targeted thereagainst |
| US5569588A (en) | 1995-08-09 | 1996-10-29 | The Regents Of The University Of California | Methods for drug screening |
| AU6941196A (en) | 1995-09-15 | 1997-04-17 | Samir Chachoua | Method for the identification and therapeutic use of disease-associated organisms, elements and forces |
| US5885806A (en) * | 1995-11-28 | 1999-03-23 | The Johns Hopkins University School Of Medicine | Methods to prepare conditionally replicating viral vectors |
| US5837464A (en) | 1996-01-29 | 1998-11-17 | Virologic, Inc. | Compositions and methods for determining anti-viral drug susceptibility and resistance and anti-viral drug screening |
| CN1263867C (zh) | 1996-01-29 | 2006-07-12 | 病毒科学公司 | 用于确定抗病毒药物敏感性和抗性和筛选抗病毒药物的组合物和方法 |
| US5945276A (en) | 1996-04-10 | 1999-08-31 | Signal Pharmaceuticals, Inc. | Reporter cell line system for detecting cytomegalovirus and identifying modulators of viral gene expression |
| US5939253A (en) | 1996-04-26 | 1999-08-17 | Diagnostic Hybrids, Inc. | Compositions and methods for detecting viral infection |
| DK0986753T4 (da) | 1997-04-07 | 2005-12-19 | Bioimage As | Fremgangsmåde til uddragning af kvantitativ information, hvad angår en påvirkning af et cellulært respons |
| WO1998046796A1 (en) | 1997-04-11 | 1998-10-22 | The Regents Of The University Of California | A method of screening nucleotide sequences to identify disruptors or effectors of biological processes or pathways |
| WO1998059074A1 (en) | 1997-06-23 | 1998-12-30 | Emory University | Human immunodeficiency viruses causing aids in a nonhuman primate |
| US5976813A (en) | 1997-12-12 | 1999-11-02 | Abbott Laboratories | Continuous format high throughput screening |
-
1997
- 1997-01-24 AU AU13168/97A patent/AU717755B2/en not_active Ceased
- 1997-01-24 PL PL97328069A patent/PL186473B1/pl not_active IP Right Cessation
- 1997-01-24 HU HU9902618A patent/HU226203B1/hu not_active IP Right Cessation
- 1997-01-24 CN CNA2006101685069A patent/CN1991365A/zh active Pending
- 1997-01-24 US US09/117,217 patent/US6221578B1/en not_active Expired - Lifetime
- 1997-01-24 NZ NZ325912A patent/NZ325912A/xx not_active IP Right Cessation
- 1997-01-24 CZ CZ19982335A patent/CZ292899B6/cs not_active IP Right Cessation
- 1997-01-24 SK SK1002-98A patent/SK283878B6/sk not_active IP Right Cessation
- 1997-01-24 DE DE69712731T patent/DE69712731T2/de not_active Expired - Lifetime
- 1997-01-24 TR TR1998/01443T patent/TR199801443T2/xx unknown
- 1997-01-24 EP EP97900712A patent/EP0877937B1/en not_active Expired - Lifetime
- 1997-01-24 ES ES97900712T patent/ES2177922T3/es not_active Expired - Lifetime
- 1997-01-24 AT AT97900712T patent/ATE217971T1/de active
- 1997-01-24 CN CN97191904A patent/CN1209875A/zh active Pending
- 1997-01-24 KR KR10-1998-0705747A patent/KR100495690B1/ko not_active IP Right Cessation
- 1997-01-24 WO PCT/IB1997/000071 patent/WO1997027480A1/en not_active Application Discontinuation
- 1997-01-24 IL IL12544297A patent/IL125442A/en not_active IP Right Cessation
- 1997-01-24 BR BR9707204-4A patent/BR9707204A/pt not_active Application Discontinuation
- 1997-12-27 ZA ZA9700669A patent/ZA97669B/xx unknown
-
1998
- 1998-07-16 NO NO19983300A patent/NO321329B1/no not_active IP Right Cessation
- 1998-07-20 IS IS4799A patent/IS4799A/is unknown
- 1998-08-20 BG BG102710A patent/BG102710A/xx unknown
-
2000
- 2000-12-14 US US09/735,487 patent/US6528251B2/en not_active Expired - Fee Related
-
2003
- 2003-01-15 US US10/342,188 patent/US20030152917A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP0877937B1 (en) | Method of assessing the chemotherapy of hiv-positive patients based on the phenotypic drug sensitivity of the patient's hiv strains | |
| Felber et al. | A quantitative bioassay for HIV-1 based on trans-activation | |
| Shibata et al. | Mutational analysis of the human immunodeficiency virus type 2 (HIV-2) genome in relation to HIV-1 and simian immunodeficiency virus SIV (AGM) | |
| Accola et al. | A putative α-helical structure which overlaps the capsid-p2 boundary in the human immunodeficiency virus type 1 Gag precursor is crucial for viral particle assembly | |
| Kellam et al. | Recombinant virus assay: a rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates | |
| Michael et al. | Defective accessory genes in a human immunodeficiency virus type 1-infected long-term survivor lacking recoverable virus | |
| Verhoef et al. | Strict control of human immunodeficiency virus type 1 replication by a genetic switch: Tet for Tat | |
| US6509018B1 (en) | Non-M non-O HIV strains, fragments and uses | |
| Jármy et al. | Phenotypic analysis of the sensitivity of HIV‐1 to inhibitors of the reverse transcriptase, protease, and integrase using a self‐inactivating virus vector system | |
| Wiskerchen et al. | Identification and characterization of a temperature-sensitive mutant of human immunodeficiency virus type 1 by alanine scanning mutagenesis of the integrase gene | |
| JPH05501654A (ja) | 霊長類レンチウイルスワクチン | |
| CA2244735C (en) | Method of managing the chemotherapy of patients who are hiv positive based on the phenotypic drug sensitivity of human hiv strains | |
| Salminen et al. | Construction and biological characterization of infectious molecular clones of HIV-1 subtypes B and E (CRF01_AE) generated by the polymerase chain reaction | |
| Leguern et al. | Single amino acid change in Tat determines the different rates of replication of two sequential HIV-1 isolates | |
| Laakso et al. | Replicative fidelity of lentiviral vectors produced by transient transfection | |
| RU2174014C2 (ru) | Способ определения оптимальной химиотерапии пациентов, серопозитивных по вич, основанный на фенотипической лекарственной чувствительности человеческих штаммов вич | |
| Safari et al. | Functional and Structural Segregation of Overlapping Helices in HIV-1 | |
| US20040038199A1 (en) | Phenotyping assay and reagents therefor | |
| US20100009341A1 (en) | Methods and means for assessing hiv gag/protease inhibitor therapy | |
| Iglesias-Sánchez et al. | Each genomic RNA in HIV-1 heterozygous virus generate new virions | |
| Kalyanaraman et al. | Homologous recombination between human immunodeficiency viral DNAs in cultured human cells: analysis of the factors influencing recombination | |
| US5753490A (en) | Recombinant HIV and modified packaging cells and method for treating acquired immune deficiency syndrome | |
| CN108486161A (zh) | 一种hiv指示细胞系及其制备方法 | |
| Palmer et al. | Murine leukemia virus with a primer-binding site complementary to tRNALys, 3 adapts to select new tRNAs for replication following extended in vitro culture | |
| Kelly et al. | Forced selection of tRNAGlu reveals the importance of two adenosine-rich RNA loops within the U5-PBS for SIVsmmPBj replication |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees |